Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 6 studies | 28% ± 7% | |
| respiratory goblet cell | 6 studies | 54% ± 21% | |
| club cell | 5 studies | 35% ± 12% | |
| secretory cell | 5 studies | 37% ± 19% | |
| squamous epithelial cell | 4 studies | 27% ± 10% | |
| duct epithelial cell | 3 studies | 57% ± 11% |
Insufficient scRNA-seq data for expression of PI3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 44% | 13271.55 | 638 / 1445 | 80% | 2905.68 | 146 / 183 |
| intestine | 40% | 1256.67 | 384 / 966 | 72% | 763.45 | 381 / 527 |
| lung | 52% | 603.31 | 300 / 578 | 41% | 778.91 | 469 / 1155 |
| tonsil | 0% | 0 | 0 / 0 | 78% | 1866.05 | 35 / 45 |
| peripheral blood | 75% | 3804.44 | 694 / 929 | 0% | 0 | 0 / 0 |
| stomach | 13% | 144.96 | 45 / 359 | 62% | 599.24 | 176 / 286 |
| skin | 53% | 964.41 | 963 / 1809 | 11% | 307.55 | 54 / 472 |
| uterus | 4% | 127.88 | 6 / 170 | 60% | 1825.61 | 274 / 459 |
| pancreas | 0% | 2.95 | 1 / 328 | 55% | 418.05 | 98 / 178 |
| ovary | 1% | 1.93 | 2 / 180 | 47% | 230.73 | 202 / 430 |
| spleen | 40% | 336.75 | 96 / 241 | 0% | 0 | 0 / 0 |
| bladder | 0% | 0 | 0 / 21 | 39% | 1095.58 | 199 / 504 |
| breast | 28% | 167.26 | 129 / 459 | 6% | 55.96 | 70 / 1118 |
| prostate | 25% | 214.44 | 61 / 245 | 6% | 10.64 | 30 / 502 |
| liver | 3% | 9.69 | 7 / 226 | 7% | 32.65 | 28 / 406 |
| brain | 0% | 0.40 | 3 / 2642 | 7% | 31.86 | 48 / 705 |
| adipose | 4% | 26.35 | 52 / 1204 | 0% | 0 | 0 / 0 |
| kidney | 0% | 0 | 0 / 89 | 4% | 12.49 | 36 / 901 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 9.66 | 1 / 29 |
| heart | 2% | 5.07 | 13 / 861 | 0% | 0 | 0 / 0 |
| adrenal gland | 1% | 8.24 | 2 / 258 | 0% | 1.13 | 1 / 230 |
| thymus | 0% | 4.95 | 2 / 653 | 1% | 2.22 | 4 / 605 |
| blood vessel | 1% | 6.51 | 10 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 0% | 1.87 | 3 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007620 | Biological process | copulation |
| GO_0018149 | Biological process | peptide cross-linking |
| GO_0045087 | Biological process | innate immune response |
| GO_0019731 | Biological process | antibacterial humoral response |
| GO_0001533 | Cellular component | cornified envelope |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005829 | Cellular component | cytosol |
| GO_0005576 | Cellular component | extracellular region |
| GO_0031012 | Cellular component | extracellular matrix |
| GO_0004866 | Molecular function | endopeptidase inhibitor activity |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0030280 | Molecular function | structural constituent of skin epidermis |
| Gene name | PI3 |
| Protein name | Elafin (Elastase-specific inhibitor) (ESI) (Peptidase inhibitor 3) (PI-3) (Protease inhibitor WAP3) (Skin-derived antileukoproteinase) (SKALP) (WAP four-disulfide core domain protein 14) |
| Synonyms | WAP3 WFDC14 |
| Description | FUNCTION: Neutrophil and pancreatic elastase-specific inhibitor of skin. It may prevent elastase-mediated tissue proteolysis. Has been shown to inhibit the alpha-4-beta-2/CHRNA2-CHRNB2 nicotinic acetylcholine receptor and to produce a weak inhibition on Kv11.1/KCNH2/ERG1 and on the transient receptor potential cation channel subfamily V member 1 (TRPV1) . . |
| Accessions | P19957 ENST00000243924.4 |
